Insider trade

Director sold ~$137K of HALO shares in the open market

Traded Nov 10, 2025 · Filed Nov 12, 2025

Why it stands out

A board member of Halozyme sold $137K of Halozyme shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$136,960

Shares × reported transaction price

Timing vs results

7 days after results of Nov 3, 2025, 79 days before results of Jan 28, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−3.1%	−2.9%	−0.2%
30 days	−10.9%	+1.3%	−12.2%
90 days	+11.7%	+3.0%	+8.7%
180 days	−0.4%	+9.8%	−10.2%

Past results only. Not a forecast.

The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

10mo ago

Compensation award — excluded from discretionary-purchase analysis.

Scheduled in advance10mo ago

10mo ago

Gift or transfer — classified separately from trades.